Bausch Health Canada Adds PrOKEDI Doses to Quebec Drug List
Bausch Health's Canadian unit secures RAMQ formulary listing for PrOKEDI, expanding patient access in Quebec.
If you've been following Bausch Health (BHC), here's a quiet but meaningful update out of Canada: the company's Canadian subsidiary has officially listed PrOKEDI dosages on the RAMQ formulary — that's the Quebec public drug insurance plan that determines which medications are covered for millions of residents in the province.
Getting onto the RAMQ formulary is kind of a big deal for any pharma company. It essentially means eligible Quebec residents covered under the province's public drug plan can now access PrOKEDI with insurance support, rather than paying out of pocket. For Bausch Health, that translates into a broader potential patient base and a more predictable revenue stream from the Canadian market.
Read more Gray Media Buys 6 TV Stations From American Spirit for $50M →
Bausch Health has been working to stabilize and grow its business amid ongoing corporate restructuring, and moves like this — incremental formulary wins in key markets — are part of how specialty pharma companies build sustainable commercial footing. A listing in a major provincial formulary can meaningfully influence prescribing patterns, since physicians are more likely to recommend a drug when patients can actually afford it.
While the source details on this particular announcement are limited, formulary inclusions are generally the result of months of negotiations between a drug manufacturer and provincial drug review bodies, involving price, clinical evidence, and cost-effectiveness data. So this listing reflects a process that likely started well before today's announcement.
For investors keeping tabs on BHC's recovery story, watching these market access milestones in both the US and Canada offers a clearer picture of the company's commercial momentum than quarterly earnings alone. Continue reading at Yahoo Finance.
